Litcius/Paper detail

OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity

Kate Poropatich, Donye Dominguez, Wen‐Ching Chan, Jorge Andrade, Yuanyuan Zha, Brian Wray, Jason Miska, Lei Qin, Lisa E. Cole, Sydney Coates, Urjeet A. Patel, Sandeep Samant, Bin Zhang

2020Journal of Clinical Investigation82 citationsDOIOpen Access PDF

Abstract

Plasmacytoid DCs (pDCs), the major producers of type I interferon, are principally recognized as key mediators of antiviral immunity. However, their role in tumor immunity is less clear. Depending on the context, pDCs can promote or suppress antitumor immune responses. In this study, we identified a naturally occurring pDC subset expressing high levels of OX40 (OX40+ pDC) enriched in the tumor microenvironment (TME) of head and neck squamous cell carcinoma. OX40+ pDCs were distinguished by a distinct immunostimulatory phenotype, cytolytic function, and ability to synergize with conventional DCs (cDCs) in generating potent tumor antigen-specific CD8+ T cell responses. Transcriptomically, we found that they selectively utilized EIF2 signaling and oxidative phosphorylation pathways. Moreover, depletion of pDCs in the murine OX40+ pDC-rich tumor model accelerated tumor growth. Collectively, we present evidence of a pDC subset in the TME that favors antitumor immunity.

Topics & Concepts

ImmunityTumor microenvironmentCancer researchImmunologyImmune systemMedicineBiologyImmunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers
OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity | Litcius